study

A picture of a human brain

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-Resistant Depression (TRD)

HMNC Brain Health ("HMNC'' or the "Company"), a global clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, together with Develco Pharma, a company specializing in the development and manufacture of orally administered modified, prolonged & chrono release drugs today announced promising top-line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-release formulation of ketamine (KET01) in Treatment-Resistant Depression (TRD).
1 2 3 4 5 6 7 8 9 10  

Recommended Stories

Real Time Analytics